<DOC>
	<DOCNO>NCT02899299</DOCNO>
	<brief_summary>The purpose study test effectiveness tolerability combination Nivolumab Ipilimumab compare Pemetrexed Cisplatin Carboplatin patient unresectable pleural mesothelioma .</brief_summary>
	<brief_title>Study Nivolumab Combined With Ipilimumab Versus Pemetrexed Cisplatin Carboplatin First Line Therapy Unresectable Pleural Mesothelioma Patients</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Males Females least 18 year age Histologically confirm pleural malignant mesothelioma eligible curative surgery ECOG Performance status 0 1 Available tumor sample test Acceptable blood work Primitive peritoneal , pericardial tunica vaginalis testis mesothelioma Prior chemotherapy pleural mesothelioma Prior treatment antiPD1 , antiPDL1 , antiPDL2 orantiCTLA4 antibody History malignancy unless subject diseasefree least 3 year Active , untreated central nervous system ( CNS ) metastasis Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>